Plain-English translation of NCT07399678 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called to see if it is safe and works well for people who are overweight or obese. The study will give some participants the medication as injections under the skin, while others receive a placebo (a dummy injection with no medicine). Researchers will carefully watch how the medication affects the body and whether it helps with weight management.
Many people struggle with weight loss and the health problems that come with it, especially when combined with type 2 diabetes. This medication is being tested to see if it could offer a new treatment option for people who have tried other approaches.
You likely qualify if…
You likely don't qualify if…
Participants will come to the study site for regular visits over several weeks or months. You will receive injections of either the new medication or a placebo under your skin. The study team will monitor you closely with blood tests, check your vital signs, and ask about any side effects. You will also be randomly assigned to either receive the medication or placebo, so you won't know which one you're getting during the study.
AI-generated summary from trial data · Jul 10, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Alveus Therapeutics, Inc.
Enrollment target
~180 participants
Started
December 2025
Primary completion
April 2027
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Study Director
Alveus Therapeutics
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.